AnaBios News

SAN DIEGO, CA – October 15, 2021 – The National Center for Advancing Translational Sciences (NCATS) has chosen a multidisciplinary team of computational scientists and experimentalists from AnaBios and the Georgia Institute of Technology as one of four groups to progress to the next round in the 2020 NCATS ASPIRE Reduction-to-Practice Challenge. The winning project of the AnaBios-Georgia Tech team is entitled, “Development of a Comprehensive Integrated Platform for Translational Innovation in Pain, Opioid Abuse Disorder and Overdose.” Led by principal investigator Jeffrey Skolnick, Ph.D., from Georgia Tech and co-investigator Andre Ghetti, Ph.D., Chief Executive Officer of AnaBios, the team [...]

SAN DIEGO, CA – September 30, 2021 – The National Institute of Neurological Disorders and Stroke (NINDS), part of the the National Institutes of Health (NIH), has awarded AnaBios a $1,734,409 Small Business Innovation Research (SBIR) grant through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to advance the development of its novel analgesic, ANB-504. The new compound was initially developed using PhaseX®, AnaBios’ unique human-based translational paradigm, which helps overcome the limitations of the current pain drug discovery strategy by generating human-relevant and clinically predictive data at the preclinical stage. AnaBios is developing ANB-504, a lead [...]

AnaBios is pleased to announce that Stanford University researchers David Yeomans, PhD, and Justin Meyerowitz, MD, PhD, are the winners of our first annual Translational Research Grant Award. The Stanford researchers will obtain up to $15,000 in AnaBios high-quality human tissue samples to be used for their project determining the translatability of oxytocin efficacy in human cells compared to data from rodent models. Dr. Yeomans is the Director of Pain Research and Faculty of Anesthesia at Stanford University. His lab primarily focuses on distinguishing the science underlying different types of pain, identifying markers of the different pain types, and developing [...]

Nature Scientific Reports today published new research from AnaBios about the role of late sodium current inhibition in arrhythmias using adult human primary cardiomyocytes from ethically-consented donor hearts. Study findings suggest that inhibition of this conductance could prove to be an effective therapeutic strategy, and highlights the use of human ex-vivo heart models for advancing cardiac translational research. Click here to view the article. 

SAN DIEGO, CA – June 8, 2021 – The National Center for Advancing Translational Sciences (NCATS) has selected a team from AnaBios and the Georgia Institute of Technology as one of five remaining groups to advance to the next round in the 2020 NCATS ASPIRE Reduction-to-Practice Challenge. Their winning project is entitled, “Development of a Comprehensive Integrated Platform for Translational Innovation in Pain, Opioid Abuse Disorder and Overdose.” Under the leadership of Principal Investigator Jeffrey Skolnick, Ph.D., from Georgia Tech and co-investigator Andre Ghetti, Ph.D., Chief Executive Officer of AnaBios,  a multidisciplinary team of computational scientists and experimentalists will conduct [...]

SAN DIEGO, CA – June 3, 2021 – AnaBios Corporation and Cambridge Bioscience Ltd. today announced an international distributor partnership focused on providing high-quality human tissue samples to researchers in Europe and the United Kingdom. This new partnership will allow UK and European scientists to obtain ethically-consented human tissue samples for studies aimed at identifying new drug targets through transcriptomics and proteomics analysis in healthy or diseased tissues, including diabetes, chronic pain, fibrosis and heart failure. “AnaBios is excited to partner with Cambridge Bioscience as a distributor in Europe and the UK,” said Dr. Chris Mathes, AnaBios’ Chief Commercial Officer. [...]

SAN DIEGO, CA – April 6, 2021 – AnaBios Corporation announces the provision of a $15,000 grant award today for a selected academic scientist conducting translational research. AnaBios provides high-quality human tissue samples from ethically consented organ donors and is committed to enabling human-focused drug discovery in areas of high, unmet medical need, including cardiac disease, chronic pain, respiratory ailments, liver disease and kidney disease. “AnaBios is excited to provide this research grant to a researcher demonstrating the greatest need for high-quality human tissue samples in academic research,” said Dr. Chris Mathes, Chief Commercial Officer of AnaBios. “Ultimately, the outcomes [...]

The National Center for Advancing Translational Sciences (NCATS) recently highlighted AnaBios' novel screening platform as part of its social media campaign to share success stories from recipients of Small Business Innovation Research (SBIR) grants. Last year, AnaBios was awarded a SBIR grant to help develop its unique human dorsal root ganglia platform for pre-clinical drug discovery. Click to view the Twitter and LinkedIn posts.

Toxicological Sciences recently published a new study from AnaBios and Novartis scientists that evaluated the potential cardiotoxic effects of Hydroxychloroquine, Chloroquine and Azithromycin in adult human primary cardiomyocytes. Click here to access our library and read the study.

SAN DIEGO, CA – December 15, 2020 – The National Institute of Health (NIH) and its subdivision, the National Center for Advancing Translational Sciences (NCATS), has awarded AnaBios a Phase I Small Business Innovation Research (SBIR) grant to further advance its unique human dorsal root ganglia (DRG) platform for pre-clinical drug discovery. In this NIH/NCATS-sponsored program, AnaBios will develop a battery of assays for a translational drug screening platform that will generate human-relevant data to assess the potential of a drug candidate’s activity in specific pain states. “AnaBios appreciates the NIH’s continued support of our efforts to develop tools [...]

SAN DIEGO, October 29, 2020 (Newswire.com) - Today, AnaBios Corporation announced the publication of a peer-reviewed article which provides the latest example of its innovative human drug development paradigm. The work, conducted in collaboration with Orion Corporation and researchers at the Faculty of Medicine in Helsinki, Finland, and at the Faculty of Medicine, University of Szeged, Hungary, focused on a new compound targeted against a cardiac protein implicated in heart failure, ischemia and arrhythmia. The paper, entitled “Discovery and characterization of ORM-11372, a unique and positively inotropic sodium-calcium exchanger/inhibitor,” was published in the British Journal of Pharmacology. AnaBios conducts physiology experiments with [...]

AnaBios Chief Commercial Officer Dr. Chris Mathes was recently interviewed by Ion Channel Library about his career in the biotech industry, the automated patch clamp sector and AnaBios' human tissue platform. Click here to read the full interview.